HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.

Abstract
The era of interferon-free antiviral treatments for hepatitis C virus infection has arrived. With increasing numbers of approved antivirals, evaluating all parameters that may influence response is necessary to choose optimal combinations for treatment success. Targeting NS5A has become integral in antiviral combinations in clinical development. Daclatasvir and ledipasvir belong to the NS5A inhibitor class, which directly target the NS5A protein. Alisporivir, a host-targeting antiviral, is a cyclophilin inhibitor that indirectly targets NS5A by blocking NS5A/cyclophilin A interaction. Resistance to daclatasvir and ledipasvir differs from alisporivir, with mutations arising in NS5A domains I and II, respectively. Combining these two classes acting on distinct NS5A domains represents an attractive strategy for potentially effective interferon-free treatments for chronic hepatitis C infection.
AuthorsPrecious J Lim, Philippe A Gallay
JournalCurrent opinion in virology (Curr Opin Virol) Vol. 8 Pg. 30-7 (Oct 2014) ISSN: 1879-6265 [Electronic] Netherlands
PMID24879295 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
CopyrightCopyright © 2014 Elsevier B.V. All rights reserved.
Chemical References
  • Antiviral Agents
  • Benzimidazoles
  • Carbamates
  • Fluorenes
  • Imidazoles
  • Pyrrolidines
  • Viral Nonstructural Proteins
  • ledipasvir
  • Cyclosporine
  • NS-5 protein, hepatitis C virus
  • Valine
  • daclatasvir
  • alisporivir
Topics
  • Antiviral Agents (metabolism, pharmacology)
  • Benzimidazoles (metabolism, pharmacology)
  • Carbamates
  • Cyclosporine (metabolism, pharmacology)
  • Drug Resistance, Viral
  • Fluorenes (metabolism, pharmacology)
  • Hepacivirus (drug effects, enzymology)
  • Humans
  • Imidazoles (metabolism, pharmacology)
  • Mutation, Missense
  • Protein Binding
  • Pyrrolidines
  • Valine (analogs & derivatives)
  • Viral Nonstructural Proteins (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: